Pruritus Therapeutics Market Size, Share, Growth, Sales Revenue and Key Drivers Analysis Research Report by 2027

iCrowdNewswire

Sep 14, 2021

High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario, and drug development pressure on pharmaceuticals due to upcoming patent expiries are key factors contributing to high CAGR of Pruritus Therapeutics during forecast period.

According to the current analysis of Reports and Data, the Pruritus Therapeutics Market is estimated to account for over USD 19.10 Billion by 2027 from USD 11.77 Billion in 2019, registering a CAGR of approximately 6.2% through the forecast period. The Pruritus Therapeutics Market is poised to be driven by the growing prevalence of skin diseases. The study covers therapeutic agents for ‘Pruritus’ – an unpleasant sensation that stimulates desire to scratch the skin. Pruritus therapeutics are available in wide range of skin conditions and other underlying causes of pruritus. Recent emergence of TRP channels as a drug target for treatment of itching is a major disruptive finding in pruritus sector. In line with this, TRP channel antagonists, TRPM8 agonists are some of the emerging TRP channel modulation mechanisms that can be for could be used for pruritus treatment.

Rising prevalence of target diseases, unmet needs of pruritus patients pushing the drug development, significant focus of pharmaceutical companies on development of novel mechanisms based pruritus drugs,  upcoming patent expiry, availability of public as well private funds for research, and favorable regulatory scenario, are some of the key factors propelling market growth in the industry. However, associated side effects, and availability of advanced alternative treatment options such as photo therapy, are the major hindrance for market growth during 2019-2026.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1176

Further key findings from the report suggest

Pruritus Therapeutics market is growing at a CAGR of 1% in Asia Pacific followed by North America and Europe, with 6.1 % and 6.0% CAGR, respectively. High pruritus prevalence across the globe is the key factor to accelerate the market growth during forecast period across all regions.

As of 2019, Corticosteroids is the dominating pruritus therapeutics which holds 41.4% of the global market. European regional market is the chief revenue generating source for this product segment, followed by North America and Asia-Pacific regions.

Calcineurin Inhibitors is expected to be the fastest growing market segment during forecast period 2019-2026 with a CAGR of 6.9%. However, associated side effects and costs are major challenge for the market growth of this market segment.

Skin conditions disease type segment (that includes xerosis, dermatitis, psoriasis, scabies, burns & scars, insect bites and hives) . was valued at USD 7.60 billion and is expected reach USD 12.60 billion by 2026.

Asia Pacific is expected to account for the 24.3% of the global Pruritus therapeutics market. Developing nations such China, and India are likely to witness high growth

Associated side effects related to pruritus therapeutics and lack of awareness about pruritus is likely to hinder the market growth during the forecast period.

Key participants include Allergan, Astellas Pharma, Bristol-Myers Squibb, Cipla, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1176

For the purpose of this report, Reports and Data has segmented the Pruritus Therapeutics market on the basis of type, disease type, treatment type, end use, and region:

Type (Revenue, USD Million; 2017–2027)

Corticosteroids

Antihistamines

Local Anesthetics

Counterirritants

Immunosuppressant

Calcineurin Inhibitors

Others

Disease Type (Revenue, USD Million; 2017–2027)

Skin conditions

Atopic Dermatitis

Allergic Contact Dermatitis

Urticaria

Others

Internal diseases

Nerve disorders

Psychiatric diseases

Irritation and allergic reactions

Treatment Type (Revenue, USD Million; 2017–2027)

Itchy skin treatment

Corticosteroid creams and ointments

Other creams and ointments

Oral medications

End Use (Revenue, USD Million; 2017–2027)

Hospital

Clinic

Others

Regional Outlook (Revenue in USD Million; 2017–2027)

North America

Europe

Asia Pacific

Middle East & Africa

Latin America

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1176

Thank you for reading our report. For customization inquiry or further information, please connect with us and we will ensure you get the report that meets your requirements.  

Read More Reports:-

Surgical Navigation Systems Market @ https://www.medgadget.com/2020/03/surgical-navigation-systems-market-to-reach-usd-1-21-billion-by-2026.html

Antibody Production Market @ https://www.medgadget.com/2020/03/antibody-production-market-to-reach-usd-29-58-billion-by-2027.html

Cell Isolation Market @ https://www.medgadget.com/2020/03/cell-isolation-market-to-reach-usd-21-51-billion-by-2027.html

X-ray Photoelectron Spectroscopy Market @ https://www.medgadget.com/2020/03/x-ray-photoelectron-spectroscopy-market-to-reach-usd-952-34-million-by-2027.html

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Information:

John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

YOU MAY ALSO LIKE

Vancouver’s Star power grows for year three…

High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario, and drug development pressure on pharmaceuticals due…

read more

Michelin Introduces MICHELIN BETTER HAUL ROAD: Developed…

High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario, and drug development pressure on pharmaceuticals due…

read more

Michelin Debuts Mining Industry’s First Energy-Efficient Tire,…

High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario, and drug development pressure on pharmaceuticals due…

read more